PARP inhibitorFDA-approvedSecond-line
Niraparib
How it works
Blocks an enzyme that helps repair DNA damage, making cancer cells more susceptible to death.
Cancer types
Pancreatic Cancer— BRCA-mutated
Ovarian Cancer— BRCA1/2-mutated
Efficacy
Niraparib has been shown to improve progression-free survival in patients with BRCA1/2-mutated ovarian cancer, with a median progression-free survival of approximately 21 months.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Ovarian Cancer Trial Examines SBRT and Niraparib Combination | Ovarian Cancer | phase-2 | — | Source → |
| Study Examines Niraparib-Plus-Pembrolizumab for Lung Cancer Maintenance Therapy | Lung Cancer | phase-3 | The median progression-free survival was 5.55 months for both treatment arms. | Source → |
| Evaluating Tuvusertib in Combination with Niraparib or Lartesertib for Epithelial Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Testing Niraparib in Advanced Lung Cancer Patients with Specific Genetic Marker | Lung Cancer | phase-2 | — | Source → |
| Testing Niraparib and Neratinib in Advanced Solid Tumors and Ovarian Cancer | Ovarian Cancer | phase-1 | — | Source → |
| Risk Factors for Niraparib-induced Anemia in Japanese Ovarian Cancer Patients | Ovarian Cancer | observational | — | Source → |
| Evaluating Niraparib for Ovarian Cancer Treatment | Ovarian Cancer | preclinical | — | Source → |
| Testing Niraparib in Ovarian Cancer Patients with Limited Spread | Ovarian Cancer | phase-2 | — | Source → |
| Heated Chemotherapy and Niraparib for Advanced Ovarian and Peritoneal Cancers | Ovarian Cancer | phase-3 | — | Source → |
| New Treatment Combination Shows Promise for Men with Advanced Prostate Cancer | Prostate Cancer | phase-3 | Median radiographic progression-free survival was 38.6 months in the niraparib + AAP group versus 8.3 months in the placebo + AAP group. | Source → |
| Evaluating a New Treatment Combination for Recurrent Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Combination Therapy for Advanced Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Testing Niraparib and Copanlisib in Advanced Ovarian and Endometrial Cancer | Ovarian Cancer | phase-1 | — | Source → |
| Niraparib's Safety and Effectiveness in Ovarian Cancer Treatment | Ovarian Cancer | observational | — | Source → |
| Niraparib May Lower Platelet Count in Ovarian Cancer Patients | Ovarian Cancer | observational | — | Source → |
| Niraparib May Offer Better Progression-Free Survival for Ovarian Cancer Patients | Ovarian Cancer | observational | The median progression-free survival was 13.77 months in the bevacizumab group. | Source → |
| Niraparib Safety and Effectiveness in Older Patients with Tubo-Ovarian Cancer | Ovarian Cancer | observational | Progression-free survival was 12 months (95%CI: 2.0-25.0) for patients aged 50-64, 29 months (95%CI: 11.0-52.0) for patients aged 65-74, and 16 months (95%CI: 1.0-31.0) for patients aged 75 and older. | Source → |
| Combining Medications May Help Prostate Cancer Patients | Prostate Cancer | phase-3 | The primary endpoint was met, with a significant improvement in radiographic progression-free survival observed, with a hazard ratio of 0.63. | Source → |
| Ovarian Cancer Cells May Become More Sensitive to Treatment | Ovarian Cancer | lab-study | The resistance indices for A2780/NRP and OVCAR3/NRP were 8.95 and 4.42, respectively. | Source → |
| Corneal Deposits Linked to Cancer Treatment | Ovarian Cancer | observational | — | Source → |
| New Treatment Combination Shows Modest Progression-Free Survival Benefit in Advanced Ovarian Cancer | Ovarian Cancer | phase-3 | The primary endpoint was investigator-assessed progression-free survival (PFS) as per RECIST v1.1, with a median of 20.6 months in arm 3 versus 19.2 months in arm 2. | Source → |
| Ovarian Cancer Treatment Linked to Heart Problems in Some Patients | Ovarian Cancer | lab-study | — | Source → |
| Niraparib Shows Promise in Treating Advanced Melanoma | Melanoma | phase-2 | The disease control rate was 64%. | Source → |
| Rare Blood Platelet Deficiency Linked to Cancer Drug | Ovarian Cancer | observational | — | Source → |
| Real-world study of ovarian cancer treatment reveals patient experiences | Ovarian Cancer | observational | — | Source → |
| Combining Cancer Drugs May Improve Ovarian Cancer Treatment | Ovarian Cancer | phase-3 | Patients receiving maintenance niraparib who reported concomitant use of statins exhibited significantly improved PFS compared with those on placebo with concomitant statins (HR = 0.34; P < 0.001; median PFS 18.2 vs. 6.0 months). | Source → |
| Individualized Dose of Niraparib Reduces Hematologic Adverse Event Costs | Ovarian Cancer | phase-3 | The total mean calculated AE management cost per patient was $12,987.71 with the FSD and $6744.93 with the ISD. | Source → |
| Real-world outcomes of ovarian cancer patients on niraparib-bevacizumab maintenance therapy | Ovarian Cancer | phase-2 | Median time to treatment discontinuation was 11.8 months (95% CI 8.7 to 13.5), and median time to next treatment was 14.1 months (95% CI 11.3 to 16.6). | Source → |
| Niraparib Side Effects: Researchers Identify Risk Factors for Nausea and Vomiting | Ovarian Cancer | observational | — | Source → |
| Niraparib Maintenance Therapy in Ovarian Cancer: Long-Term Survival Results | Ovarian Cancer | phase-3 | The 5-year PFS rate numerically favored niraparib in the overall (niraparib, 22%; placebo, 12%) and HRd populations (niraparib, 35%; placebo, 16%). | Source → |
| Niraparib May Improve Survival in Ovarian Cancer Patients | Ovarian Cancer | observational | Median overall survival was 24.1 months in the niraparib group and 18.4 months in the active surveillance group. | Source → |
| Niraparib Efficacy and Safety in Japanese Women with Ovarian Cancer | Ovarian Cancer | phase-2 | Confirmed objective response rate was 60.0% (90% confidence interval [CI]=39.4-78.3) | Source → |
| Combining Cancer Treatments May Improve Effectiveness | Ovarian Cancer | lab-study | — | Source → |
| PARP Inhibitors Linked to Cardiovascular Risks in Ovarian Cancer Patients | Ovarian Cancer | observational | — | Source → |
| Adjusting Dose of Cancer Drug Niraparib May Improve Safety | Ovarian Cancer | phase-3 | — | Source → |
| Niraparib as Maintenance Therapy for Ovarian Cancer in Japan | Ovarian Cancer | observational | — | Source → |
| Niraparib Dose Adjusted for Safety in Ovarian Cancer Patients | Ovarian Cancer | phase-3 | — | Source → |
| Niraparib Efficacy and Safety in Ovarian Cancer | Ovarian Cancer | observational | Median overall survival was 30 months, and median progression-free survival was 8 months. | Source → |
| New Treatment Combination Shows Modest Activity in Advanced Ovarian Cancer | Ovarian Cancer | phase-2 | The objective response rate was 17.1% (80% CI, 9.8 to 27.0), including one complete response (2.4%). | Source → |
| Rare Lung Disease Linked to Ovarian Cancer Drug | Ovarian Cancer | observational | — | Source → |
| Olaparib and Niraparib Maintenance Treatments for Ovarian Cancer | Ovarian Cancer | phase-2 | The median progression-free survival of 117 patients was 20.1 months. | Source → |
| Niraparib Tested for Rare Genetic Mutation in Gastrointestinal Cancers | Pancreatic Cancer | phase-2 | — | Source → |
| Niraparib therapy linked to increased creatinine levels in ovarian cancer patients | Ovarian Cancer | observational | — | Source → |
| Measuring PARP Inhibitors in Ovarian Cancer Patients | Ovarian Cancer | lab-study | — | Source → |
| Adjusting Cancer Treatment Dose Based on Patient Weight and Platelet Count | Ovarian Cancer | phase-3 | Efficacy in patients who received FSD or ISD was similar for the overall (FSD hazard ratio [HR], 0.59 [95% CI, 0.46-0.76] vs. ISD HR, 0.69 [95% CI, 0.48-0.98]) and the homologous recombination-deficient (FSD HR, 0.44 [95% CI, 0.30-0.64] vs. ISD HR, 0.39 [95% CI, 0.22-0.72]) populations. | Source → |
| New Combination Therapy Shows Promise for Advanced Prostate Cancer | Prostate Cancer | phase-3 | Median radiographic progression-free survival was 16.6 months in the niraparib + AAP group compared with 10.9 months in the placebo + AAP group. | Source → |
| Choosing the Right Maintenance Therapy for Advanced Ovarian Cancer | Ovarian Cancer | phase-3 | — | Source → |
| PARP Inhibitor Use in Gynecological Cancer Patients Compared | Ovarian Cancer | observational | — | Source → |
| Niraparib's Cost Impact on Ovarian Cancer Treatment | Ovarian Cancer | phase-3 | — | Source → |
| Niraparib May Improve Progression-Free Survival in Lung Cancer Patients | Lung Cancer | phase-3 | Median progression-free survival was 1.54 months with niraparib and 1.36 months with placebo. | Source → |
| Combining Medications May Help Overcome Ovarian Cancer Resistance | Ovarian Cancer | lab-study | — | Source → |
| New Uses for PARP Inhibitors in Ovarian Cancer Treatment | Ovarian Cancer | review | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.